Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022

This report describes how local and systemic reactions and myocarditis are less frequent after a homologous COVID-19 booster dose.

Related Keywords

Silver Spring ,Maryland ,United States ,James Baggs ,Johnr Su ,Tomt Shimabukuro ,Annem Hause ,Paige Marquez ,Tanyar Myers ,Philipg Blanc ,Phillipg Blanc ,Charles Licata ,Janea Gwira Baumblatt ,Bicheng Zhang ,Davidk Shay ,Julianne Gee ,Isaac Mccullum ,Community Health Systems Inc ,International Committee Of Medical Journal Editors ,Us Department Of Health ,Human Services ,Us Department ,Drug Administration ,Emergency Response Team ,Advisory Committee On Immunization Practices ,Pfizer ,Department Of Health ,Emily Jane Woo ,Advisory Committee ,Immunization Practices ,Vaccine Adverse Event Reporting System ,Medical Dictionary ,Regulatory Activities ,Response Team ,International Committee ,Medical Journal Editors ,Community Health Systems ,Vaccine Adverse Event Reporting ,Booster Doses Among Adults ,Mortal Wkly ,Mortality Weekly Report ,Covid 19 Vaccine Safety ,Covid 19 Booster Dose Safety ,Covid 19 Local And Systemic Vaccination Reactions ,Less Local And Systemic Reactions After Booster Dose ,Covid 19 Booster Dose Has Less Pain Fatigue Headaches ,Covid 19 Booster Dose Less Myocarditis Reactions ,